Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | PTGIR | P43119 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2919409 | 0.84 | S1PR1 (0.48) | SMN1; SMN2SIGMAR1DRD4POLB | |
| SCHEMBL2921985 | 0.84 | S1PR5 (0.46) | SIGMAR1DRD4DRD2DRD3GRM2 | |
| SCHEMBL2919442 | 0.83 | S1PR5 (0.44) | SIGMAR1DRD4GRM2 | |
| SCHEMBL2910904 | 0.82 | SIGMAR1 (0.57) | SIGMAR1DRD2DRD3 | |
| SCHEMBL2921823 | 0.82 | FUCA1 (0.50) | SIGMAR1DRD4DRD2DRD3ACHE | |
| SCHEMBL2917808 | 0.81 | SIGMAR1 (0.52) | SMN1; SMN2SIGMAR1DRD4ACHE | |
| SCHEMBL2432513 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2SIGMAR1DRD4PTGIRDRD2 | |
| SCHEMBL15958463 | 0.78 | SMN1; SMN2 (0.57) | SMN1; SMN2SIGMAR1DRD4PTGIRDRD2 | |
| SCHEMBL15399382 | 0.78 | SMN1; SMN2 (0.57) | SMN1; SMN2SIGMAR1DRD4PTGIRDRD2 | |
| SCHEMBL2918073 | 0.77 | SIGMAR1 (0.57) | SMN1; SMN2SIGMAR1DRD4PTGIRHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784407-B1 | 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF | KOREA RES INST CHEM TECH (KR) | 2010-09-08 | — | — | EP | disclosed |
| US-7662810-B2 | Potassium(1R,5S,6S)-2-(1-benzyl-azetidine-3-yl-thio)-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate; antibacterial activities against Grampositive and Gramnegative bacteria and excellent antibacterial activities against resistant bacteria such as methicillin resistant Staphylococcus aureus | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-02-16 | — | — | US | disclosed |
| EP-1784407-A4 | 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF | KOREA RES INST CHEM TECH (KR) | 2009-02-11 | — | — | EP | disclosed |
| US-20070244089-A1 | 2- Arylmethylazetidine Carbapenem Derivatives and Preparation Thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-10-18 | — | — | US | disclosed |
| EP-1784407-A1 | 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF | Korea Research Institute of Chemical Technology (KR) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006025634-A1 | 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244089-A1 | 2- Arylmethylazetidine Carbapenem Derivatives and Preparation Thereof | SCN9A, SCN2A, SCN5A | SMN1; SMN2 1150/4885SIGMAR1 2493/4885DRD4 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.